Ординатура / Офтальмология / Английские материалы / Essentials in Ophthalmology Oculoplastics and Orbit_Guthoff, Katowitz_2007
.pdf278 |
Subject Index |
|
|
|
|
|
|
|
|||
|
– |
nasolacrimal duct |
|
|
– |
postoperative |
EUGOGO. see also European |
||||
|
|
|
obstruction (CNLDO) 219, |
|
|
|
hemorrhage 186 |
|
|
Group on Graves’ |
|
|
|
|
221 |
|
|
– |
shape 191 |
|
|
Orbitopathy consortium |
|
|
conjunctiva 183 |
|
|
– |
size 191 |
European Group on |
|||||
|
– |
disease 65 |
|
|
– |
upper eyelid 187 |
|
|
Graves’ Orbitopathy |
||
|
– |
Muller’s complex 51, 52 |
|
– |
grafting 182 |
|
|
(EUGOGO) 145 |
|||
|
– |
retractor flap 67 |
|
Desmarres retractor 51, 52, |
|
euthyroidism 144 |
|||||
|
|
corneal transplantation 207 |
|
|
54, 174 |
excision 20 |
|||||
|
CosmoDerm 250 |
|
dexamethasone 102 |
exenteration 196 |
|||||||
|
CosmoPlast 250 |
|
diazepam 222 |
– |
indication 196 |
||||||
|
COX-2 126 |
|
diplopia 147, 148 |
|
exophthalmos 2, 147, 148 |
||||||
|
cranial nerve 90 |
|
– |
decompression- |
exposure keratopathy 45, 47, |
||||||
|
CTLA-4. see also cytotoxic |
|
|
induced 147 |
|
|
48, 58, 144, 146 |
||||
|
|
|
T lymphocyte antigen |
|
– |
post-decompression 148 |
extracellular matrix |
||||
|
Cutler-Beard bridge flap 30, |
|
DON. see also dysthyroid optic |
|
|
(ECM) 127 |
|||||
|
|
|
31 |
|
|
|
neuropathy (DON) |
|
extraconal space 94 |
||
|
cytochrome b 102 |
dyschromias 229 |
extrinsic aging 260 |
||||||||
|
cytotoxic T lymphocyte |
|
dysthyroid optic neuropathy |
eyeball 78 |
|||||||
|
|
|
antigen (CTLA-4) 129 |
|
|
(DON) 145, 146 |
– |
dystopia 149 |
|||
|
|
|
|
|
|
dystopias 38 |
eyelid |
||||
|
|
|
|
|
|
|
|
|
– |
cheek continuum 70 |
|
|
|
|
|
|
|
|
|
|
– |
reconstruction 29 |
|
|
|
|
D |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
– |
retraction 45, 61, 63 |
||
|
|
|
|
|
|
E |
|
||||
|
|
|
|
|
|
|
|
||||
|
dacryocystitis 223 |
|
|
|
– retraction of the lower |
||||||
|
|
|
|
|
|||||||
|
– |
acute 223 |
|
“eye popping” reflex 46 |
|
|
lid 63 |
||||
|
|
dacryocystography 221 |
|
ecchymosis 239 |
– retraction of the upper |
||||||
|
dacryocystorhinostomy |
|
ECM. see also extracellular |
|
|
lid 45 |
|||||
|
|
|
(DCR) 75, 219, 224 |
|
|
matrix |
|
|
|
||
|
– |
in children 224 |
ectropion 1, 3, 5, 6, 10, 12, 220 |
|
|
|
|||||
|
|
Dalrymple’s sign 62 |
|
– |
involutional 10 |
|
|
|
|||
|
|
|
|
|
F |
||||||
|
DCR. see |
|
– |
repair 6 |
|
|
|||||
|
|
|
|
|
|||||||
|
|
|
also dacryocystorhinostomy |
|
– |
under-correction 12 |
F-BUT. see also fluorescein |
||||
|
|
|
(DCR) |
|
Edinger-Westphal nucleus 92 |
|
|
break-up time |
|||
|
debulking 15 |
|
enophthalmos 153, 167 |
face-lift operation 239 |
|||||||
|
decompression surgery 143, |
|
– |
anophthalmic 153 |
facial |
||||||
|
|
|
144, 147 |
|
– |
correction 167 |
– |
aging 230, 231 |
|||
|
|
dermabrasion 262, 264, 270 |
|
ENT examination 221 |
|
|
– soft tissue deflation 230 |
||||
|
– |
endpoint 270 |
|
entropion 1, 5, 10, 11, 12, 220 |
– |
lipoatrophy 251, 252, 254 |
|||||
|
|
DermaDeep 252 |
|
– |
involutional 11 |
|
|
– HIV-related 251, 254 |
|||
|
dermal fat 251 |
|
– |
repair 10 |
– |
nerve paralysis 62 |
|||||
|
DermaLive 252 |
|
– |
under-correction 12 |
– |
reconstruction 197 |
|||||
|
dermis fat 184 |
|
enucleation 185 |
– |
rejuvenation 259 |
||||||
|
– |
graft 161, 165, 181 |
|
epinephrine 79 |
– |
sculpting 248 |
|||||
|
– |
transplantation 184 |
|
epiphora 10, 35, 172, 219 |
– |
skin flap 195 |
|||||
|
dermofat |
|
Er:YAG laser 269 |
FAMI. see also fat autograft |
|||||||
|
– |
graft 186, 187, 191, 192 |
|
– |
endpoint 269 |
|
|
muscle injection |
|||
|
|
|
– |
atrophy 186 |
|
erythema 260, 271 |
fasciomuscular cone 93 |
||||
|
|
|
– |
motility 192 |
|
erythromycin ointment 54, 58 |
fat atrophy 191 |
||||
|
|
|
– |
necrosis 186 |
|
ethmoidal artery 75, 83, 86, 95 |
fat autograft muscle injection |
||||
|
|
|
|
|
|
ethmoid bone 74 |
|
|
(FAMI) 251 |
||
|
|
|
|
|
|
|
Subject Index |
279 |
|
Feldman’s corset |
|
– |
steroid therapy 107 |
|
– |
hypoesthesia 149 |
|
||
|
platysmaplasty 236 |
|
hepatocyte growth factor |
|
insulin-like growth factor 1 |
|
|||
fibroblast activation 125 |
|
|
(HGF) 178 |
|
|
(IGF1) 178 |
|
||
fibrosis 148 |
|
Hering’s law 46 |
|
intercanthal line 2, 3 |
|
||||
filling agent 248 |
|
herpes |
|
intercellular adhesion molecule |
|
||||
fistula 220 |
|
– |
simplex virus 271 |
|
|
(ICAM) 127 |
|
||
fluorescein break-up time (F- |
|
– |
zoster infection 62 |
|
interleukin 6 102 |
|
|||
|
BUT) 214 |
|
Hertel |
|
International Society for |
|
|||
FP. see also fractional |
|
– |
exophthalmometry 47 |
|
|
the Study of Vascular |
|
||
|
photothermolysis (FP) |
|
– |
measurement 156 |
|
|
Anomalies (ISSVA) 115 |
|
|
fractional photothermolysis |
|
HGF. see also hepatocyte |
|
intraconal |
|
||||
|
(FP) 269, 270 |
|
|
growth factor |
|
– |
fat 94 |
|
|
frontalis muscle 203 |
|
HIV. see also human |
|
– |
space 93 |
|
|||
– |
transfer 197, 203 |
|
|
immunodeficiency virus |
|
irregular skin texture 229 |
|
||
frontal nerve 91 |
HLA haplotype 129 |
|
isotretinoin 262 |
|
|||||
frozen section control 22 |
|
hot socket 187 |
|
ISSVA. see also International |
|
||||
full-thickness |
|
Hughes flap 34 |
|
|
Society for the Study of |
|
|||
– |
blepharotomy 57 |
|
human immunodeficiency |
|
|
Vascular Anomalies |
|
||
– |
skin graft 34, 35 |
|
|
virus (HIV) 247 |
|
|
|
|
|
|
|
|
hyaluronan 124, 125, 127, 128, |
|
|
|
|
|
|
|
|
|
|
248 |
|
|
|
|
|
|
|
|
|
|
|
J |
|
|
|
|
|
hyaluronic acid (HA) 248 |
|
|
|
|
|||
|
G |
|
|
|
|||||
|
|
|
|
|
|
||||
|
|
hydrodissection 1 |
|
Jessner’s solution 265 |
|
||||
|
|
|
|
|
|||||
galea capitis 199 |
|
hydroquinone 263 |
|
jowl 232 |
|
||||
GD. see also Graves’ disease |
|
hydroxyapatite (HA) 171, 172, |
|
Juenemann probe 224 |
|
||||
|
(GD) |
|
|
173, 178 |
|
|
|
|
|
glaucoma 47 |
|
– |
exposure 172 |
|
|
|
|
|
|
globe deformity 163 |
|
– |
implant 173 |
|
|
|
|
|
|
|
|
|
K |
|
|
||||
glucocorticoid 102, 149 |
|
– |
orbital implant 171 |
|
|
|
|
||
|
|
|
|
|
|
||||
glycolic acid 265 |
|
hydroxylapatite silicone |
|
Kallmann syndrome 154 |
|
||||
Goldenhar syndrome 220 |
|
|
implant 165 |
|
keratolytic 264, 265 |
|
|||
gonococcal infection 221 |
|
hyperpigmentation 271 |
|
keratoplasty 215 |
|
||||
Grave’s |
hyperthyroidism 125 |
|
Kestenbaum spectacle 192 |
|
|||||
– |
disease (GD) 61, 123, 130 |
|
hypo-osmolar salivary |
|
Koebner phenomenon 262 |
|
|||
– |
ophthalmopathy 77, 95 |
|
|
tear 209 |
|
|
|
|
|
Grove’s sign 62 |
|
hypopigmentation 266, 271 |
|
|
|
|
|
||
guanethidine 47 |
|
hypoxia 129 |
|
|
|
|
|
||
|
|
|
L |
|
|
||||
gustatory reflex epiphora 212 |
|
Hyrtl’s canal 94 |
|
|
|
|
|||
|
|
lacrimal |
|
||||||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
– |
artery 85 |
|
|
|
|
|
|
|
|
– |
gland 81 |
|
|
|
H |
|
|
I |
|
||||
|
|
|
|
– |
nerve 91 |
|
|||
|
|
|
ICAM. see also intercellular |
|
|
||||
H-zone 24 |
|
|
– |
sac 75 |
|
||||
HA. see also hyaluronic acid |
|
|
adhesion molecule |
|
lacrimal system 219, 222, 225 |
|
|||
Hasner’s membrane 219, 224 |
IFN-γ 123 |
|
– |
fistula 225 |
|
||||
hemangioma 100, 103, 107, |
|
IGF1. see also insulin-like |
|
– |
intubation 222 |
|
|||
|
108 |
|
|
growth factor 1 |
|
lagophthalmos 45 |
|
||
– |
capillary 100 |
IL-1α 124 |
|
laser 266 |
|
||||
– |
growth 108 |
|
infraorbital |
|
– |
non-ablative 266 |
|
||
– |
in children 104 |
|
– |
artery 88 |
|
– |
resurfacing 264, 268 |
|
|
280 |
Subject Index |
|
|
|
|
|
|
||
|
lateral canthus 2, 5, 9, 185, 202 |
|
microvascular |
ocular |
|||||
|
lateral tarsal strip 70 |
|
|
anastomosis 209, 213, 217 |
– |
cicatricial pemphigoid 214 |
|||
|
lentigo maligna 26, 27 |
|
MIRAGel 167 |
– |
surface reconstruction 208 |
||||
|
leukoregulin 127 |
|
Mohs micrographic |
oculofacial prosthesis 201, 204 |
|||||
|
levator |
|
|
surgery 13, 14, 15, 22 |
oculomotor |
||||
|
– |
aponeurosis 56, 62, 174, |
|
– |
errors 22 |
– |
muscle 79 |
||
|
|
|
176 |
|
– |
periocular tumor 14 |
– |
nerve 76, 82, 91 |
|
|
– |
disinsertion/ |
|
– |
steps 15 |
|
oculoplastic surgery 229 |
||
|
|
|
mullerectomy 55 |
|
Mohs specimen 18 |
OK-432 118 |
|||
|
– |
Muller’s complex 49 |
|
– |
gross sectioning 18 |
ophthalmic |
|||
|
– |
muscle 78 |
|
– |
mapping 18 |
– |
artery 81, 82, 93, 95 |
||
|
|
lid 27. see also eyelid |
|
MTZ. see also microthermal |
|
|
– embryology 82 |
||
|
– |
laxity 9, 27 |
|
|
zone |
– |
vein 89, 94 |
||
|
– |
laxity correction 9 |
mucocele 224 |
optic |
|||||
|
– |
malposition 27 |
|
mucous membrane |
– |
nerve 78, 84, 93 |
|||
|
– |
margin 4 |
|
|
transplantation 207 |
|
|
– artery 84 |
|
|
– |
motility 5 |
|
Muller’s muscle 54, 62, 77, |
– |
neuropathy 144 |
|||
|
– |
retraction test 27 |
|
|
171, 210 |
oral mucus membrane |
|||
|
|
lip augmentation 254 |
|
– |
flap 174, 176, 178 |
|
|
graft 200 |
|
|
liposuction 234, 239 |
|
|
– surgical technique 174 |
|
orbicularis muscle 2, 10, 11 |
|||
|
Lockwood’s ligament 80 |
|
muscular artery 86, 87 |
orbital 4 |
|||||
|
lower lid 2 |
|
muscular vascularization 87 |
– |
anatomy 73 |
||||
|
– |
crease 4 |
|
Mustarde |
– |
apex 76 |
|||
|
– |
position 2 |
|
– |
lid-sharing flap 30 |
– |
cavity 196 |
||
|
– |
retraction 63 |
|
– |
lid-sharing rotation flap 33 |
|
|
– reconstruction 196 |
|
|
– |
retractor 1 |
|
– |
rotating cheek flap 34 |
– |
compartment |
||
|
– |
tumor 38 |
|
mylohyoid muscle 237 |
|
|
syndrome 119 |
||
|
|
Lyme’s disease 62 |
|
myofibroblast 128 |
– |
decompression 48 |
|||
|
lymphangioma 113, 115 |
|
|
|
– |
exenteration 195 |
|||
|
– |
classification 115 |
|
|
|
– |
fat 4, 93 |
||
|
lymphatic vessels in the |
|
|
|
– |
fibroblast 126, 128 |
|||
|
|
|
N |
||||||
|
|
|
orbit 90 |
|
|
– |
floor 74 |
||
|
|
|
|
|
|
||||
|
lymphoid hypertrophy 117 |
|
N-vinyl pyrrolidone 153 |
– |
periosteum 77 |
||||
|
|
|
|
|
nasociliary nerve 76, 92, 94 |
– |
rim 76 |
||
|
|
|
|
|
nasolacrimal duct 37, 220 |
– |
roof 74 |
||
|
|
|
|
|
nasopharynx 37 |
– |
septum 4 |
||
|
|
|
M |
||||||
|
|
|
|
neck |
– |
vein 89 |
|||
|
|
|
|
|
|||||
|
malar region 232 |
|
– |
aging 233 |
orbitomalar ligament 68 |
||||
|
medial canthus 34, 36 |
|
– |
laxity 241 |
orbitotomy 117 |
||||
|
– |
defect 36 |
|
– |
liposuction 236 |
osseointegration implant 201 |
|||
|
– |
reconstruction 34 |
|
necrosis 186 |
osteotomy 145, 224 |
||||
|
|
medial orbital wall 75 |
|
|
|
|
|
|
|
|
meibomian gland 25 |
|
|
|
|
|
|
||
|
melanoma 26 |
|
|
|
|
|
|
||
|
|
|
O |
|
|
P |
|||
|
meningolacrimal artery 85 |
|
|
|
|
||||
|
|
|
|
PAI-1. see also plasminogen |
|||||
|
methyl methacrylate 153 |
|
Obagi |
||||||
|
meticulous tissue mapping 21 |
|
– |
Blue Peel 266 |
|
|
activator inhibitor type 1 |
||
|
microphthalmos 153, 154, |
|
– |
system 260 |
palate graft 67 |
||||
|
|
|
156, 160, 166 |
|
oblique muscle 88 |
palpebral artery 88 |
|||
|
microthermal zone |
|
OCT. see optical coherence |
parotid duct transposition 212 |
|||||
|
|
|
(MTZ) 269 |
|
|
tomography (OCT) |
|
|
|
|
|
|
|
|
|
|
Subject Index |
281 |
PDT. see photodynamic |
prosthesis motility 165 |
silicone |
|
|||||
|
therapy (PDT) |
pseudoproptosis 61 |
– |
tissue expander 166 |
|
|||
pediatric hemangioma 106 |
pseudoretraction 46, 61 |
– |
tube 225 |
|
||||
– |
blood velocity 106 |
ptosis surgery 7 |
sinusitis 149 |
|
||||
pegging 178 |
|
|
Sjögren’s syndrome 211 |
|
||||
pellet |
|
|
|
skin 232, 234 |
|
|||
– |
expander 155, 158, 159 |
|
|
– |
aging 229 |
|
||
|
R |
|
||||||
– |
implantation 165 |
|
– |
eczema 10 |
|
|||
|
|
|
||||||
pemphigoid 65 |
radiotherapy 24 |
– |
evaluation 232 |
|
||||
periocular |
Ramsay Hunt syndrome 62 |
– |
hydrodissection 234 |
|
||||
– |
malignancy 23 |
RANTES 125 |
– |
rejuvenation 259 |
|
|||
– |
sebaceous carcinoma 26 |
recombinant human basic |
– |
resurfacing 262, 268, 271 |
|
|||
– |
tumor 13, 14, 15, 21, 27 |
|
fibroblast growth factor |
|
– |
complication 271 |
|
|
|
– |
debulking 15 |
|
(Rh-bFGF) 178 |
|
– |
laser 268 |
|
|
– |
excision 13 |
rectangular graft 67 |
sliding and rotating cheek |
|
|||
|
– |
reconstructive |
rectus muscle 79, 87, 182, 183 |
|
flap 39 |
|
||
|
|
technique 27 |
reticular dermis 263 |
sliding glabellar flap 36 |
|
|||
|
– |
treatment 14 |
retractor 6, 7, 66 |
SLO. see scanning laser |
|
|||
periorbital drainage 90 |
– |
fixation 6 |
|
ophthalmoscope |
|
|||
PESS. see also postenucleation |
– |
laxity 7 |
SMAS. see also superficial |
|
||||
|
socket syndrome |
– |
lower lid 1 |
|
musculoaponeurotic |
|
||
petrolatum 264 |
– |
recessing 66 |
|
system; see also superficial |
|
|||
phenol peel 266 |
retroauricular flap 241 |
|
musculoaponeurotic layer |
|
||||
photodamage 259 |
retrogenia 233 |
– |
lift 239 |
|
||||
photothermolysis 268 |
Rh-bFGF. see also recombinant |
SMASectomy 241 |
|
|||||
phthisical |
|
human basic fibroblast |
SMG. see also submandibular |
|
||||
– |
eye 188 |
|
growth factor |
|
gland |
|
||
– |
globe 161 |
rheumatoid arthritis 124 |
snap-back test 5, 27 |
|
||||
phthisis 166 |
rhytidectomy 234, 235, 237 |
sodium |
|
|||||
plasminogen activator |
rhytides 229 |
– |
morrhuate 118 |
|
||||
|
inhibitor type 1 |
Rosenmüller fold 222 |
– |
tetradecyl sulfate 119 |
|
|||
|
(PAI-1) 127 |
|
|
solar elastosis 263 |
|
|||
platysmaplasty 235, 237, 239 |
|
|
SOOF. see also suborbicularis |
|
||||
plethora 46 |
|
|
|
oculi fat |
|
|||
|
S |
|
|
|||||
PMMA. see also polymethyl |
|
spacer graft 67, 69 |
|
|||||
|
|
|
||||||
|
methacrylate microsphere |
S-lift 241, 243 |
spectrogram 101 |
|
||||
poly-L-lactic acid 251, 252 |
– |
with SMASectomy 241, 243 |
sphenoethmoidal nerve of |
|
||||
polyalkylimide 253 |
saliva 209 |
|
Luschka 86 |
|
||||
polymethylmethacrylate |
salivary epiphora 214, 215 |
sphenoid bone 74 |
|
|||||
|
(PMMA) microsphere 253 |
scarring 271 |
spiral of Tillaux 79 |
|
||||
postenucleation socket |
Schirmer’s test 146, 211, 214, |
squamous cell carcinoma 17, |
|
|||||
|
syndrome (PESS) 164, 165, |
|
217 |
|
19, 23, 24 |
|
||
|
187, 189 |
sciatic tuberosity 183 |
– |
immunosuppressed host 24 |
|
|||
posterior |
sclerocornea 159 |
staphylococcus aureus 223, |
|
|||||
– |
ciliary artery 84 |
sclerotherapy 119 |
|
271 |
|
|||
– |
lamella 20 |
– |
image-guided 119 |
Stensen’s duct 208, 212 |
|
|||
– |
lid lamella 2 |
Sculptra 251, 252 |
sternocleidomastoid |
|
||||
pre-aponeurotic fat 49, 54 |
sebaceous |
|
muscle 235 |
|
||||
pretarsal orbicularis 63 |
– |
carcinoma 25 |
steroid 272 |
|
||||
PRL. see preferred retinal locus |
– |
gland 19 |
– |
therapy 107 |
|
|||
proptosis 22, 61, 114, 186 |
secretion test 221 |
|
|
|
|
|||
282 |
Subject Index |
|
|
|
|
|
|
||
|
Stevens-Johnson |
|
thyroid-related |
– |
computed tomography 116 |
||||
|
|
|
syndrome 211, 214 |
|
– |
ophthalmopathy 64 |
– |
laser treatment 117 |
|
|
|
Stevens scissors 51 |
|
– |
orbitopathy (TRO) 143 |
– |
magnetic resonance |
||
|
strabismus 143, 144, 149 |
|
thyroid eye disease 45, 46 |
|
|
imaging 116 |
|||
|
streptococcus 223 |
|
thyrotropin receptor |
– |
OK-432 118 |
||||
|
subconjunctival cyst 186 |
|
|
(TSHR) 124 |
– |
sclerotherapy 117 |
|||
|
submandibular gland |
|
TIMP. see also tissue inhibitor |
– |
sodium morrhuate 118 |
||||
|
|
|
(SMG) 207 |
|
|
of metalloproteinasis |
– |
surgical resection 117 |
|
|
suborbicularis oculi fat |
|
tissue inhibitor of |
venous drainage 214 |
|||||
|
|
|
(SOOF) 68 |
|
|
metalloproteinasis |
VEP. see also visual evoked |
||
|
|
subplatysmal fat 235 |
|
|
(TIMP) 127 |
|
|
potential |
|
|
sun-damage 26 |
|
T lymphocyte 130 |
vicryl suture 177 |
|||||
|
sunblock 263 |
|
TNF-α 123, 131 |
visual evoked potential |
|||||
|
superficial musculoaponeurotic |
|
transplantation minor labial |
|
|
(VEP) 155 |
|||
|
|
|
layer (SMAS) 232 |
|
|
salivary gland 210 |
VLM. see also venous- |
||
|
superficial musculoaponeurotic |
|
transposition flap 38 |
|
|
lymphatic malformation |
|||
|
|
|
system (SMAS) 68 |
|
tretinoin 263 |
|
|
(VLM) |
|
|
|
supernumerary muscle 80 |
|
triamcinolone acetonide 272 |
von Graefe’s sign 62 |
||||
|
supraorbital artery 85 |
|
trichiasis 4 |
|
|
|
|||
|
suprarenin 224 |
|
trichloroacetic acid |
|
|
|
|||
|
systemic steroid 117 |
|
|
(TCA) 264, 265 |
|
|
|
||
|
|
|
|
|
W |
||||
|
|
|
|
|
trigeminal nerve 76, 90 |
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
TRO. see also thyroid-related |
“witches chin” deformity 233 |
|||
|
|
|
|
|
|
orbitopathy |
wedge resection 31 |
||
|
|
|
T |
|
|
||||
|
|
|
trochlear nerve 76, 90, 91 |
Westcott scissors 51, 54 |
|||||
|
|
|
|
||||||
|
TAO. see also thyroid- |
|
TSHR. see also thyrotropin |
Wharton’s duct 212 |
|||||
|
|
|
associated orbitopathy |
|
|
receptor; see also TSH |
Whitnall’s |
||
|
tarsal border 7 |
|
|
receptor |
– |
ligament 79 |
|||
|
tarsoconjunctiva 10 |
TSH receptor (TSHR) 146 |
– |
orbital tubercle 74 |
|||||
|
– |
keratinization 10 |
|
tumescent infiltration 234 |
|
|
|
||
|
– |
pedicle flap 177 |
|
tumor 37 |
|
|
|
||
|
|
tarsorrhaphy 48, 199, 200 |
|
– |
nasopharynx 37 |
|
|
|
|
|
|
|
|
|
X |
||||
|
TCA. see also trichloroacetic |
|
|
|
|
|
|||
|
|
|
acid |
|
|
|
xanthelasma 259 |
||
|
T cell 125, 127 |
|
|
|
|
|
|
||
|
|
|
U |
|
|
|
|||
|
– |
activation 127 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|||
|
– |
autoimmune reactivity 125 |
|
upper lid retraction 45, 47 |
|
|
|
||
|
|
|
|
Y |
|||||
|
– |
infiltration 124 |
|
– |
thyroid-related 47 |
|
|
||
|
|
|
|
|
|||||
|
|
temporalis muscle 197, 203 |
|
|
|
Yersinia enterocolitica 129 |
|||
|
– |
flap 197 |
|
|
|
|
|
|
|
|
– |
transposition 203 |
|
|
|
|
|
|
|
|
|
|
V |
|
|
|
|||
|
|
Tenon’s capsule 80, 177, 183 |
|
|
|
|
|
||
|
|
|
|
|
|
Z |
|||
|
|
|
|
|
|
|
|||
|
Tenzel semicircular flap 29 |
|
vascular endothelial growth |
|
|
||||
|
|
|
|
|
|||||
|
thermal necrosis 269 |
|
|
factor (VEGF) 102 |
zinc chloride 14 |
||||
|
thrombosis for the ophthalmic |
|
vasculopathy 145 |
Zinn’s tendon 79 |
|||||
|
|
|
vein 119 |
|
VEGF. see also vascular |
zyderm 248 |
|||
|
thyroid-associated orbitopathy |
|
|
endothelial growth factor |
zygomatico-orbital |
||||
|
|
|
(TAO) 123, 124 |
|
venous-lymphatic |
|
|
foramen 74 |
|
|
– |
resolution of |
|
|
malformation (VLM) 113, |
|
zyplast 248 |
||
|
|
|
inflammation 124 |
|
|
116, 117, 118 |
|
|
|
